Plain-English translation of NCT06658405 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether Gardasil 9, an HPV vaccine, can help women over 45 who have been treated for high-grade precancerous cervical lesions and still test positive for HPV. The study will track whether the medication helps clear the virus from the body and prevents the lesions from coming back or turning into cancer over the next two years.
Most HPV vaccines are given to younger women before they're exposed to the virus. This trial asks whether this treatment could also help older women who already have persistent HPV and have already had precancerous changes removed—potentially preventing cancer from developing.
You likely qualify if…
You likely don't qualify if…
If you join the vaccinated group, you will receive the HPV vaccine (Gardasil 9) as a series of injections on a specific schedule. You will attend follow-up visits to check your HPV status, monitor for any side effects from the vaccine, and watch for any signs of lesion recurrence or cancer over approximately two years. The study will compare your outcomes with women who chose not to be vaccinated to see if the vaccine makes a difference.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
France
Sponsor
Centre Oscar Lambret
Collaborators
Canceropôle Nord Ouest
Enrollment target
~85 participants
Started
January 2025
Primary completion
October 2028
Age range
45 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Emilie HEYMAN-DECOUPIGNY
Centre Oscar Lambret
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.